For years, Depo-Provera, commonly referred to as the birth control shot, was marketed as one of the simplest ways to prevent pregnancy. Just four shots per year and no daily pill, millions of women in the U.S. have used the contraceptive.
Now, it’s becoming one of the fastest-growing pharmaceutical mass torts in U.S. history, with no sign of the litigation slowing.
Between February and May this year, the number of Depo-Provera brain tumor lawsuits jumped from 2,100 to nearly 3,800.
Women across the country allege that long-term use (minimum one year) of the birth control shot caused meningiomas, tumors that form in the membranes surrounding the brain and spinal cord. While these types of tumors are often noncancerous, they can still lead to devastating complications. Plaintiffs have reported that Depo-Provera caused them seizures, vision loss, and cognitive impairment, and required invasive brain surgery to remove at least one, but often several, tumors.
But what makes the birth control lawsuits especially explosive? It’s not just the rapid increase in cases; it’s the growing focus on what Pfizer allegedly knew, when they knew it, and whether American women were warned the same way women in other countries were.
Recent Depo-Provera tumor lawsuits have unearthed documents that allegedly show Pfizer knew in as far back as 1983 that certain hormone-sensitive tumors, like meningiomas, could respond to an active ingredient in the birth control shot.
While attorneys are confident in the evidence, Pfizer continues to double down on weakening or outright eliminating many of the lawsuits on a legal principle involving state laws and federal regulation.
They argue that federal preemption laws should bar state-law failure to warn claims because the company couldn’t add stronger warnings without approval by the FDA. Because of this, the manufacturer says a significant portion of cases should be dismissed. It wasn’t until December 2025 that Pfizer added a tumor risk to Depo-Provera’s warning label.
With these recent developments in the Depo-Provera brain tumor MDL, the litigation has become one of the most closely-watched, high-profile pharmaceutical mass torts ever seen. Here’s more on the latest details.
Why is the Birth Control Tumor MDL Growing so Quickly?
The federal MDL has nearly 3,800 lawsuits, and attorneys continue to report a surge in new filings and client inquiries. As the Depo-Provera lawsuits continue to grow at an unusually fast pace, the reasons behind the surge are clear.
A combination of the sheer number of women who have used the birth control shot, scientific studies that show significant increased risks of meningiomas, and the fact that there were no tumor warnings are the driving force behind the pharmaceutical litigation.
Awareness is another key factor in the Depo-Provera tumor filings. Social media platforms, Reddit forums, and women’s health groups have raised awareness of the health risks of the birth control shot. It’s led former users to question whether the symptoms they experienced for years may be linked to the drug.
The New Allegation Reshaping Depo-Provera Lawsuits
One of the most important recent developments in the birth control tumor MDL involves new evidence that connects medroxyprogesterone acetate – an ingredient in Depo, to meningiomas growth. And this evidence alleges Pfizer knew of the risks in 1983.
These documents are quickly becoming central to the Depo-Provera brain tumor MDL because it seems to undermine any claim by the manufacturer that the tumor risks were unforeseeable or newly discovered. Cases hinge on allegations that women used the birth control shot for years, sometimes decades, without being adequately warned about possible tumor risks.
It’s highlighted another facet to the litigation, one that goes beyond whether the drug caused tumors. Now, it’s whether consumers were denied information that would have affected their decision to use Depo-Provera.
Long-Term Depo-Provera Users May Become Key Plaintiffs
Something less talked about but that may alter the direction of the birth control shot MDL is related to duration of use. Many lawsuits involve women who received Depo injections continuously for years, often beginning in adolescence or early adulthood.
These plaintiffs allege they remained on the drug because it was repeatedly promoted as convenient and safe for ongoing use.
Dangerous drug attorneys are increasingly focusing on whether longer-term Depo-Provera users faced substantially higher risks of meningiomas and if cumulative exposure matters. They’re also focused on whether Pfizer provided doctors with adequate guidance for long-term use of the birth control shot.
This angle could become critical to the Depo-Provera tumor MDL because millions of women used the contraceptive for extended periods of time.
Pfizer’s Defense Could Eliminate Many Birth Control Lawsuits
As the MDL continues to grow, Pfizer is relying heavily on what’s known as federal preemption. Under this argument, pharmaceutical companies may avoid certain state-law failure to warn claims if federal regulators controlled the product label language and the manufacturer couldn’t add stronger warnings without FDA approval.
If courts accept these broad preemption arguments, a significant number of Depo-Provera brain meningioma lawsuits could be dismissed. However, if their position doesn’t hold up in court, the lawsuits could gain serious momentum, propelling settlement discussions to compensate women who developed brain tumors from prolonged use of the birth control shot.
All eyes are on whether this legal argument prevails. And with bellwether trials set for later this year, both sides will see how strong their cases may play out in court.
This is a rapidly growing and rapidly changing pharmaceutical mass tort. By the time bellwether trials begin, there could be several thousand more cases in the Depo-Provera MDL.
The next phase of the litigation could determine whether the birth control shot becomes one of the U.S.’s largest dangerous pharmaceutical cases in recent history.
